ExodusPoint Capital Management’s ADC Therapeutics ADCT Stock Holding History

ExodusPoint Capital Management’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,280	Closed	-$72.3K	–	1522
2026 Q1	$72.3K	Sell	19,280 -37,503	-66%	-$148K	﹤0.01%	1452
2025 Q4	$200K	Buy	56,783 +10,842	+24%	+$44K	﹤0.01%	1387
2025 Q3	$184K	Buy	+45,941	New	+$145K	﹤0.01%	1398
2022 Q4	–	Sell	-369,386	Closed	-$1.78M	–	1588
2022 Q3	$1.78M	Buy	369,386 +230,194	+165%	+$1.67M	0.02%	845
2022 Q2	$1.11M	Buy	+139,192	New	+$1.32M	0.01%	1034
2020 Q4	–	Sell	-81,624	Closed	-$2.69M	–	1905
2020 Q3	$2.69M	Buy	81,624 +64,199	+368%	+$2.78M	0.05%	311
2020 Q2	$816K	Buy	+17,425	New	+$661K	0.02%	846

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

ExodusPoint Capital Management's ADCT Position: Q2 2026 in Review

ExodusPoint Capital Management sold out of ADC Therapeutics (ADCT) in Q2 2026, closing a stake of 19,280 shares — an estimated $72.3K sold.

ExodusPoint Capital Management first reported a position in ADCT in Q2 2020 and held it in 7 quarters. The position peaked at $2.69M in Q3 2020. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

ExodusPoint Capital Management reported no remaining ADC Therapeutics position as of Q2 2026 after selling out during the quarter.
ExodusPoint Capital Management sold 19,280 ADC Therapeutics shares in Q2 2026, an estimated $72.3K.
ExodusPoint Capital Management first reported a position in ADC Therapeutics in Q2 2020 and held it in 7 quarters.
ExodusPoint Capital Management's ADC Therapeutics position peaked at $2.69M in Q3 2020.
114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.